BKC 007
Alternative Names: BKC007Latest Information Update: 28 Oct 2019
At a glance
- Originator Boryung Pharmaceutical
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dyslipidaemias; Hypertension
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Dyslipidaemias in South Korea
- 28 Oct 2019 No recent reports of development identified for phase-I development in Hypertension in South Korea
- 01 Sep 2016 Phase-I clinical trials in Dyslipidaemias in South Korea (unspecified route) (Boryung Pharmaceuticals pipeline, August 2016)